Report by the ACNP Task Force on Response and Remission in Major Depressive Disorder
The DOI matches its Crossref record; 130 of the 132 references it cites were found in a registry or an index.
Abstract
This report summarizes recommendations from the ACNP Task Force on the conceptualization of remission and its implications for defining recovery, relapse, recurrence, and response for clinical investigators and practicing clinicians. Given the strong implications of remission for better function and a better prognosis, remission is a valid, clinically relevant end point for both practitioners and investigators. Not all depressed patients, however, will reach remission. Response is a less desirable primary outcome in trials because it depends highly on the initial (often single) baseline measure of symptom severity. It is recommended that remission be ascribed after 3 consecutive weeks during which minimal symptom status (absence of both sadness and reduced interest/pleasure along with the presence of fewer than three of the remaining seven DSM-IV-TR diagnostic criterion symptoms) is maintained. Once achieved, remission can only be lost if followed by a relapse. Recovery is ascribed after at least 4 months following the onset of remission, during which a relapse has not occurred. Recovery, once achieved, can only be lost if followed by a recurrence. Day-to-day functioning and quality of life are important secondary end points, but they were not included in the proposed definitions of response, remission, recovery, relapse, or recurrence. These recommendations suggest that symptom ratings that measure all nine criterion symptom domains to define a major depressive episode are p…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Both reports explicitly requested empirical validations of these now widely used consensus-based definitions.”
From Empirical evidence for definitions of episode, remission, recovery, relapse and recurrence in depression: a systematic review (2019) · cites this paper as Rush et al. (2006)
In the citing paper
“Not only were the specific operationalisations of the duration criteria by Frank et al. (1991) and Rush et al. (2006) not empirically supported”
From Empirical evidence for definitions of episode, remission, recovery, relapse and recurrence in depression: a systematic review (2019) · cites this paper as Rush et al. 2006
In the citing paper
“This definition of relapse is the one most commonly used in clinical studies.39”
Citations
Cites
The PHQ-9: Validity of a brief depression severity measure
Kroenke, K., Spitzer, R. L., & Williams, J. B. W. (2001) · Journal of General Internal Medicine · doi:10.1046/j.1525-1497.2001.016009606.x · Cited by 44,910
An inventory for measuring depression
BECK, A. T. (1961) · Archives of General Psychiatry · doi:10.1001/archpsyc.1961.01710120031004 · Cited by 38,032
(1992) · PubMed · Cited by 33,716
Hamilton, M. (1960) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.23.1.56 · Cited by 32,817 · cited 1×
“These reports have relied on a variety of reasonably chosen remission end points at study exit (eg, 17-item Hamilton Rating Scale for Depression p7 or p6 (HRSD17; Hamilton, 1960, 1967) or MontgomeryÄsberg Depression Rating Scale p10 (MADRS; Montgomery and Äsberg, 1979)).”
MethodThe MOS 36-ltem Short-Form Health Survey (SF-36): I. Conceptual Framework and Item Selection
Ware, J. E., & Sherbourne, C. D. (1992) · Medical Care · doi:10.1097/00005650-199206000-00002 · Cited by 30,033
A new depression scale designed to be sensitive to change
Montgomery, S. A., & Åsberg, M. (1979) · British Journal of Psychiatry · doi:10.1192/bjp.134.4.382 · Cited by 13,962
Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR)
American Psychiatric Association (2000) · doi:10.1176/appi.books.9780890423349 · Cited by 11,069
Cognitive Therapy for Depression: (675542012-001)
(2012) · PsycEXTRA Dataset · doi:10.1037/e675542012-001 · Cited by 9,663
Development of a Rating Scale for Primary Depressive Illness
HAMILTON, M. (1967) · British Journal of Social and Clinical Psychology · doi:10.1111/j.2044-8260.1967.tb00530.x · Cited by 8,410
Beck, A. T., Steer, R. A., & Brown, G. (2011) · PsycTESTS Dataset · doi:10.1037/t00742-000 · Cited by 7,535
Research works printed but not linked: 2
- American Psychiatric Association (2000b). Practice guideline for the treatment of patients with major depressive disorder (revision). Am J Psychiatry 157 (Suppl 4): 1–45.
- Weissman AN (1979). The dysfunctional attitude scale. A validation study. Diss Abst Int 40: 1389B–1390B.
Cited by
Rush, A. J., Trivedi, M. H., Wisniewski, S. R., Nierenberg, A. A., Stewart, J. W., Warden, D., Niederehe, G., Thase, M. E., Lavori, P. W., Lebowitz, B. D., et al. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.11.1905 · Cited by 5,643
Self-citationPRACTICE GUIDELINE FOR THE Treatment of Patients With Major Depressive Disorder
Gelenberg, A. J., Freeman, P. B., Markowitz, J. C., Rosenbaum, J. F., Thase, M. E., Trivedi, M. H., & Rhoads, R. S. (2010) · Cited by 1,520
Self-citationBlumberger, D. M., Vila-Rodriguez, F., Thorpe, K. E., Feffer, K., Noda, Y., Giacobbe, P., Knyahnytska, Y., Kennedy, S. H., Lam, R. W., Daskalakis, Z. J., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)30295-2 · Cited by 1,363
George, M. S., Lisanby, S. H., Avery, D., McDonald, W. M., Durkalski, V., Pavlicova, M., Anderson, B., Nahas, Z., Bulow, P., Zarkowski, P., et al. (2010) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2010.46 · Cited by 1,092
Manber, R., Edinger, J. D., Gress, J. L., Pedro-Salcedo, M. G. S., Kuo, T. F., & Kalista, T. (2008) · Sleep · doi:10.1093/sleep/31.4.489 · Cited by 868
The STAR*D project results: A comprehensive review of findings
Warden, D., Rush, A. J., Trivedi, M. H., Fava, M., & Wisniewski, S. R. (2007) · Current Psychiatry Reports · doi:10.1007/s11920-007-0061-3 · Cited by 727
“ment [7,8] because remitters function better [9] and have a better prognosis [10] than those who respond (have a symptom reduction) without remitting.”
BackgroundSelf-citationPerera, T., George, M. S., Grammer, G., Janicak, P. G., Pascual-Leone, A., & Wirecki, T. S. (2016) · Brain Stimulation · doi:10.1016/j.brs.2016.03.010 · Cited by 674
“This NIMH trial also used an active, sham-controlled condition [33] and the primary outcome focused on the clinically important endpoint of remission [34].”
MethodBerlim, M. T., van den Eynde, F., Tovar-Perdomo, S., & Daskalakis, Z. J. (2014) · Psychological Medicine · doi:10.1017/s0033291713000512 · Cited by 620
“Furthermore, our use of clinically relevant outcome measures such as response and remission rates is in line with current guidelines on the assessment of treatment efficacy in MD (Rush et al. 2006), and is clearly more useful and understandable for healthcare professionals and administrators, as well as for patients a…”
BackgroundMethodResultInfluentialFregni, F., El-Hagrassy, M. M., Pacheco-Barrios, K., Carvalho, S., Leite, J., Simis, M., Brunelin, J., Nakamura-Palacios, E. M., Marangolo, P., Venkatasubramanian, G., et al. (2021) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyaa051 · Cited by 605
Major Depression and Its Recurrences: Life Course Matters
Monroe, S. M., & Harkness, K. L. (2022) · Annual Review of Clinical Psychology · doi:10.1146/annurev-clinpsy-072220-021440 · Cited by 608
A review of vagus nerve stimulation as a therapeutic intervention
Johnson, R. L., & Wilson, C. G. (2018) · Journal of Inflammation Research · doi:10.2147/jir.s163248 · Cited by 562
“Both Bajbouj et al and Nahas et al use the same criteria for clinically significant remission, defined as the absence of clinically significant depressive symptoms.(42) Results from neuroimaging studies suggest that the mood-enhancing benefits are caused by VNS stimulation altering medial and prefrontal cortical trans…”
Vittengl, J. R., Clark, L. A., Dunn, T. W., & Jarrett, R. B. (2007) · Journal of Consulting and Clinical Psychology · doi:10.1037/0022-006x.75.3.475 · Cited by 551
Tohen, M., Frank, E., Bowden, C. L., Colom, F., Ghaemi, S. N., Yatham, L. N., Malhi, G. S., Calabrese, J. R., Nolen, W. A., Vieta, E., et al. (2009) · Bipolar Disorders · doi:10.1111/j.1399-5618.2009.00726.x · Cited by 513
“It is noteworthy that in looking at studies of unipolar disorder, Nierenberg et al. (29) found that only 17.6% of patients with a HAMD-17 score £ 7 had no symptoms of MDD.”
BackgroundInfluentialSelf-citationCollaborative Care to Improve the Management of Depressive Disorders
Thota, A. B., Sipe, T. A., Byard, G. J., Zometa, C. S., Hahn, R. A., McKnight-Eily, L. R., Chapman, D. P., Abraido-Lanza, A. F., Pearson, J. L., Anderson, C. W., et al. (2012) · American Journal of Preventive Medicine · doi:10.1016/j.amepre.2012.01.019 · Cited by 481
Self-citationMcMakin, D. L., Olino, T. M., Porta, G., Dietz, L. J., Emslie, G., Clarke, G., Wagner, K. D., Asarnow, J. R., Ryan, N. D., Birmaher, B., et al. (2012) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1016/j.jaac.2012.01.011 · Cited by 448
Nierenberg, A. A., Husain, M. M., Trivedi, M. H., Fava, M., Warden, D., Wisniewski, S. R., Miyahara, S., & Rush, A. J. (2010) · Psychological Medicine · doi:10.1017/s0033291709006011 · Cited by 458
“Remission was defined as a score f5 on the 16-item Quick Inventory of Depressive Symptomatology, Clinician-rated (QIDS-C16 ; Rush et al. 2003, 2006a ; Trivedi et al. 2004).”
BackgroundMethodSelf-citationInfluences on antidepressant prescribing trends in the UK: 1995–2011
Mars, B., Heron, J., Kessler, D., Davies, N. M., Martin, R. M., Thomas, K. H., & Gunnell, D. (2017) · Social Psychiatry and Psychiatric Epidemiology · doi:10.1007/s00127-016-1306-4 · Cited by 419
“This was based on guidance from the ACNP task force [24] who suggest recovery is ascribed after at least 4 months following the onset of remission.”
MethodBuckman, J. E. J., Underwood, A., Clarke, K., Saunders, R., Hollon, S. D., Fearon, P., & Pilling, S. (2018) · Clinical Psychology Review · doi:10.1016/j.cpr.2018.07.005 · Cited by 398
“A further distinction is made between relapse (the return of symptoms associated with the remitted episode) and recurrence (the onset of a new episode following recovery) (Rush et al., 2006).”
BackgroundMethodInfluentialBerlim, M. T., & Turecki, G. (2007) · The Canadian Journal of Psychiatry · doi:10.1177/070674370705200108 · Cited by 412
“Not achieving remission despite adequate treatment usually results in the presence of residual depressive symptoms (for example, insomnia, fatigue, psychic or somatic anxiety, and excessive reactivity to social stress) that have consistently been shown to be associated with poorer outcomes, increased risk of relapse,…”
BackgroundMethodGeorge, M. S., & Aston-Jones, G. (2010) · Neuropsychopharmacology · doi:10.1038/npp.2009.87 · Cited by 401
Bardone-Cone, A. M., Harney, M. B., Maldonado, C. R., Lawson, M. A., Robinson, D. P., Smith, R., & Tosh, A. (2010) · Behaviour Research and Therapy · doi:10.1016/j.brat.2009.11.001 · Cited by 392
“…is similar to that applied by researchers defining recovery for major depressive disorder (Frank et al., 1991; Rush et al., 2006); for example, Rush et al. (2006) argue that daily functioning should not be included in defining recovery from depression since this is affected both by the…”
ResultRush, A. J., Trivedi, M. H., Stewart, J. W., Nierenberg, A. A., Fava, M., Kurian, B. T., Warden, D., Morris, D. W., Luther, J. F., Husain, M. M., et al. (2011) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2011.10111645 · Cited by 372
Self-citationAgin-Liebes, G. I., Malone, T., Yalch, M. M., Mennenga, S. E., Ponté, K. L., Guss, J., Bossis, A. P., Grigsby, J., Fischer, S., & Ross, S. (2020) · Journal of Psychopharmacology · doi:10.1177/0269881119897615 · Cited by 360
“Clinical significance was defined as 50% or greater reduction in a score at a particular assessment point relative to baseline (Rush et al., 2006).”
BackgroundDavidson, K. W., Rieckmann, N., Clemow, L., Schwartz, J. E., Shimbo, D., Medina, V., Albanese, G., Kronish, I., Hegel, M., & Burg, M. M. (2010) · Archives of Internal Medicine · doi:10.1001/archinternmed.2010.29 · Cited by 350
Greden, J. F., Parikh, S. V., Rothschild, A. J., Thase, M. E., Dunlop, B. W., DeBattista, C., Conway, C. R., Forester, B. P., Mondimore, F. M., Shelton, R. C., et al. (2019) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2019.01.003 · Cited by 347
Self-citationKaryotaki, E., Ebert, D. D., Donkin, L., Riper, H., Twisk, J., Burger, S., Rozental, A., Lange, A., Williams, A. D., Zarski, A. C., et al. (2018) · Clinical Psychology Review · doi:10.1016/j.cpr.2018.06.007 · Cited by 303
McGrath, P. J., Stewart, J. W., Fava, M., Trivedi, M. H., Wisniewski, S. R., Nierenberg, A. A., Thase, M. E., Davis, L., Biggs, M. M., Shores-Wilson, K., et al. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.9.1531 · Cited by 350
Self-citationBlier, P., Ward, H. E., Tremblay, P., Laberge, L., Hébert, C., & Bergeron, R. (2010) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2009.09020186 · Cited by 316
Guo, T., Xiang, Y.-T., Xiao, L., Hu, C.-Q., Chiu, H. F. K., Ungvari, G. S., Correll, C. U., Lai, K. Y. C., Feng, L., Geng, Y., et al. (2015) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2015.14050652 · Cited by 308
Ising, M., Lucae, S., Binder, E. B., Bettecken, T., Uhr, M., Ripke, S., Kohli, M. A., Hennings, J. M., Horstmann, S., Kloiber, S., et al. (2009) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2009.95 · Cited by 306
Self-citationBerlim, M. T., Van den Eynde, F., & Jeff Daskalakis, Z. (2013) · Neuropsychopharmacology · doi:10.1038/npp.2012.237 · Cited by 298
“Number of responders (Rush et al, 2006a) to treatment based on the RCTs’ primary efficacy measure (defined as a X50% reduction in posttreatment scores on the Hamilton Depression Rating Scale [HAM-D] (Hamilton, 1960) or on the Montgomery–Asberg Depression Rating Scale [MADRS] (Montgomery and Asberg,…”
BackgroundMethodResultInfluentialMathew, S. J., Murrough, J. W., aan het Rot, M., Collins, K. A., Reich, D. L., & Charney, D. S. (2010) · International Journal of Neuropsychopharmacology · doi:10.1017/s1461145709000169 · Cited by 294
“Downloaded from https://academic.oup.com/ijnp/article-abstract/13/1/71/647687 by University Library user on 13 June 2018”
Spielmans, G. I., Berman, M. I., Linardatos, E., Rosenlicht, N. Z., Perry, A., & Tsai, A. C. (2013) · PLoS Medicine · doi:10.1371/journal.pmed.1001403 · Cited by 275
“Response and remission rates are often used to convey the magnitude of treatment benefit; however, these categorical measures are created arbitrarily from underlying continuous rating scale data [50].”
BackgroundKantrowitz, J., Citrome, L., & Javitt, D. (2009) · CNS Drugs · doi:10.2165/00023210-200923080-00001 · Cited by 260
Marcantoni, W. S., Akoumba, B. S., Wassef, M., Mayrand, J., Lai, H., Richard-Devantoy, S., & Beauchamp, S. (2020) · Journal of Affective Disorders · doi:10.1016/j.jad.2020.09.007 · Cited by 246
Recurrence in major depression: A conceptual analysis
Monroe, S. M., & Harkness, K. L. (2011) · Psychological Review · doi:10.1037/a0025190 · Cited by 225
Defining and Measuring Functional Recovery from Depression
Greer, T. L., Kurian, B. T., & Trivedi, M. H. (2010) · CNS Drugs · doi:10.2165/11530230-000000000-00000 · Cited by 222
Self-citationEsketamine Nasal Spray versus Quetiapine for Treatment-Resistant Depression
Reif, A., Bitter, I., Buyze, J., Cebulla, K., Frey, R., Fu, D.-J., Ito, T., Kambarov, Y., Llorca, P.-M., Oliveira-Maia, A. J., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2304145 · Cited by 222
Hasler, G., Fromm, S., Carlson, P. J., Luckenbaugh, D. A., Waldeck, T., Geraci, M., Roiser, J. P., Neumeister, A., Meyers, N., Charney, D. S., et al. (2008) · Archives of General Psychiatry · doi:10.1001/archpsyc.65.5.521 · Cited by 209
Vagal nerve stimulation for treatment-resistant depression
Carreno, F. R., & Frazer, A. (2017) · Neurotherapeutics · doi:10.1007/s13311-017-0537-8 · Cited by 208
“Just as importantly, up to 35% of patients with nonpsychotic MDD do not respond to 4 or more conventional treatments [7].”
BackgroundBerlim, M. T., Van den Eynde, F., & Daskalakis, Z. J. (2013) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2012.09.025 · Cited by 204
Partial remission, residual symptoms, and relapse in depression
Paykel, E. S. (2008) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2008.10.4/espaykel · Cited by 194
de Zwart, P. L., Jeronimus, B. F., & de Jonge, P. (2019) · Epidemiology and Psychiatric Sciences · doi:10.1017/s2045796018000227 · Cited by 189
“Specific consensus-based recommendations for these thresholds were provided in Frank et al.’s (1991) report and revised in a follow-up report by Rush et al. (2006).”
BackgroundHennings, J. M., Owashi, T., Binder, E. B., Horstmann, S., Menke, A., Kloiber, S., Dose, T., Wollweber, B., Spieler, D., Messer, T., et al. (2009) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2008.05.002 · Cited by 195
Perlis, R. H., Iosifescu, D. V., Castro, V. M., Murphy, S. N., Gainer, V. S., Minnier, J., Cai, T., Goryachev, S., Zeng, Q., Gallagher, P. J., et al. (2012) · Psychological Medicine · doi:10.1017/s0033291711000997 · Cited by 193
“The definitions for these states were drawn from prior task force reports on terminology (Frank et al. 1991 ; Rush et al. 2006).”
BackgroundMethodInfluentialIncidence and Recurrence of Late-Life Depression
Luijendijk, H. J., van den Berg, J. F., Dekker, M. J. H. J., van Tuijl, H. R., Otte, W., Smit, F., Hofman, A., Stricker, B. H. C., & Tiemeier, H. (2008) · Archives of General Psychiatry · doi:10.1001/archpsyc.65.12.1394 · Cited by 193
Garlow, S. J., Dunlop, B. W., Ninan, P. T., & Nemeroff, C. B. (2012) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2012.08.009 · Cited by 192
“…second antidepressants, atypical antipsychotics, pindolol, electroconvulsive therapy (ECT) and psychotherapies (Aronson et al., 1996; Bauer et al., 2003; Keitner et al., 2009; Maes et al., 1999; Nierenberg et al., 2006; Papkostas and Shelton, 2008; Rush et al., 2006b; Trivedi et al., 2006a).”
Self-citationKennard, B. D., Silva, S. G., Tonev, S., Rohde, P., Hughes, J. L., Vitiello, B., Kratochvil, C. J., Curry, J. F., Emslie, G. J., Reinecke, M., et al. (2009) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/chi.0b013e31819176f9 · Cited by 190
Pizzagalli, D. A., Webb, C. A., Dillon, D. G., Tenke, C. E., Kayser, J., Goer, F., Fava, M., McGrath, P., Weissman, M., Parsey, R., et al. (2018) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2018.0252 · Cited by 189
“05 to be considered statistically significant.(13) In the finalmodel, higher rACC theta activity emergedas a significant predictor of lowerweek 8HRSDscores (ie, significanteffectonthe intercept: t219 = −3.”
Self-citationFluoxetine versus placebo in preventing relapse of major depression in children and adolescents
Emslie, G. J., Kennard, B. D., Mayes, T. L., Nightingale-Teresi, J., Carmody, T., Hughes, C. W., Rush, A. J., Tao, R., & Rintelmann, J. W. (2008) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2007.07091453 · Cited by 188
Self-citationWells, A., Fisher, P., Myers, S., Wheatley, J., Patel, T., & Brewin, C. R. (2009) · Cognitive Therapy and Research · doi:10.1007/s10608-007-9178-2 · Cited by 189
“Rush et al. (2006) define recovery as 4 months with a HRSD17 score of B7 when patients are assessed every 2-weeks.”
MethodInfluentialKroenke, K., Yu, Z., Wu, J., Kean, J., & Monahan, P. O. (2014) · Pain Medicine · doi:10.1111/pme.12537 · Cited by 187
Frontal EEG predictors of treatment outcome in major depressive disorder
Iosifescu, D. V., Greenwald, S., Devlin, P., Mischoulon, D., Denninger, J. W., Alpert, J. E., & Fava, M. (2009) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2009.06.001 · Cited by 185
Self-citationHollon, S. D., DeRubeis, R. J., Fawcett, J., Amsterdam, J. D., Shelton, R. C., Zajecka, J., Young, P. R., & Gallop, R. (2014) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2014.1054 · Cited by 179
RetractedSerotonin transporter gene hypomethylation predicts impaired antidepressant treatment response
Domschke, K., Tidow, N., Schwarte, K., Deckert, J., Lesch, K.-P., Arolt, V., Zwanzger, P., & Baune, B. T. (2014) · The International Journal of Neuropsychopharmacology · doi:10.1017/s146114571400039x · Cited by 178
The neurobiology of the EEG biomarker as a predictor of treatment response in depression
Baskaran, A., Milev, R., & McIntyre, R. S. (2012) · Neuropharmacology · doi:10.1016/j.neuropharm.2012.04.021 · Cited by 178
“Very few patients who receive adequate pharmacotherapy will achieve remission defined as absence or near absence of symptoms (Rush et al., 2006).”
BackgroundTwo-year outcome of vagus nerve stimulation in treatment-resistant depression
Bajbouj, M., Merkl, A., Schlaepfer, T. E., Frick, C., Zobel, A., Maier, W., O'Keane, V., Corcoran, C., Adolfsson, R., Trimble, M., et al. (2010) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e3181db8831 · Cited by 178
“Given that remission status predicts better functioning and a more favorable prognosis for this group of patients, achievement of remission should be the goal for both treatment and clinical trials.(4) However, achieving sustained response and remission remains a major challenge in the long-term management of patients…”
Na, K.-S., Lee, K. J., Lee, J. S., Cho, Y. S., & Jung, H.-Y. (2014) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2013.09.006 · Cited by 176
“However, despite the substantial disease burden ofMDD, the remission ratewith antidepressants is only approximately 60–70% (Rush et al., 2006).”
Practice Parameter on the Use of Psychotropic Medication in Children and Adolescents
Walkup, J. (2009) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/chi.0b013e3181ae0a08 · Cited by 173
Kriesche, D., Woll, C. F. J., Tschentscher, N., Engel, R. R., & Karch, S. (2023) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-022-01479-5 · Cited by 171
“Consequently, in Boeker’s “recovered” sample there is an inclusion of patients responding well to the treatment, but not remitted according to the ACNP Task Force [60].”
ResultLópez-López, J. A., Davies, S. R., Caldwell, D. M., Churchill, R., Peters, T. J., Tallon, D., Dawson, S., Wu, Q., Li, J., Taylor, A., et al. (2019) · Psychological Medicine · doi:10.1017/s003329171900120x · Cited by 161
Does Study Design Influence Outcome?
Rutherford, B. R., Sneed, J. R., & Roose, S. P. (2009) · Psychotherapy and Psychosomatics · doi:10.1159/000209348 · Cited by 158
Dubin, M. J., Mao, X., Banerjee, S., Goodman, Z., Lapidus, K. A. B., Kang, G., Liston, C., & Shungu, D. C. (2016) · Journal of Psychiatry and Neuroscience · doi:10.1503/jpn.150223 · Cited by 156
“9 [21–68] 37.”
Comprehensive Analysis of Remission (COMPARE) with Venlafaxine versus SSRIs
Nemeroff, C. B., Entsuah, R., Benattia, I., Demitrack, M. A., Sloan, D. M., & Thase, M. E. (2007) · Biological Psychiatry · doi:10.1016/j.biopsych.2007.06.027 · Cited by 183
Self-citationAvissar, M., Powell, F., Ilieva, I., Respino, M., Gunning, F. M., Liston, C., & Dubin, M. J. (2017) · Brain Stimulation · doi:10.1016/j.brs.2017.07.002 · Cited by 152
“However, depressive symptoms and treatment response was assessed using the more general HAMD24.”
MethodInfluentialGut Microbiota in Anxiety and Depression: Unveiling the Relationships and Management Options
Kumar, A., Pramanik, J., Goyal, N., Chauhan, D., Sivamaruthi, B. S., Prajapati, B. G., & Chaiyasut, C. (2023) · Pharmaceuticals · doi:10.3390/ph16040565 · Cited by 154
“Up to 35% of people are estimated to experience treatment-resistant depression [17].”
BackgroundPredictors of Attrition During Initial (Citalopram) Treatment for Depression: A STAR*D Report
Warden, D., Trivedi, M. H., Wisniewski, S. R., Davis, L., Nierenberg, A. A., Gaynes, B. N., Zisook, S., Hollon, S. D., Balasubramani, G. K., Howland, R., et al. (2007) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2007.06071225 · Cited by 147
Self-citationMicroRNA mediators of early life stress vulnerability to depression and suicidal behavior
Allen, L., & Dwivedi, Y. (2020) · Molecular Psychiatry · doi:10.1038/s41380-019-0597-8 · Cited by 147
Ong, J. C., Shapiro, S. L., & Manber, R. (2009) · EXPLORE · doi:10.1016/j.explore.2008.10.004 · Cited by 146
Metacognitive therapy in treatment-resistant depression: A platform trial
Wells, A., Fisher, P., Myers, S., Wheatley, J., Patel, T., & Brewin, C. R. (2012) · Behaviour Research and Therapy · doi:10.1016/j.brat.2012.02.004 · Cited by 145
“Rush et al. (2006) define recovery as 4 months with a HRSD-17 score of 7 when patients are assessed every two weeks.”
BackgroundMethodInfluentialThe Economic Burden of Treatment-Resistant Depression
Olchanski, N., McInnis Myers, M., Halseth, M., Cyr, P. L., Bockstedt, L., Goss, T. F., & Howland, R. H. (2013) · Clinical Therapeutics · doi:10.1016/j.clinthera.2012.09.001 · Cited by 146
Association of the COMT val158met Variant with Antidepressant Treatment Response in Major Depression
Baune, B. T., Hohoff, C., Berger, K., Neumann, A., Mortensen, S., Roehrs, T., Deckert, J., Arolt, V., & Domschke, K. (2007) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301462 · Cited by 154
“…published ACNP task force guidelines on response and remission in major depressive disorder, which recommend monitoring of changes within a subject (for whom initial severity is fixed) rather than comparing response rates between subjects for whom initial values range widely (Rush et al, 2006).”
BackgroundHypothalamic‐Pituitary‐Adrenocortical Axis: Neuropsychiatric Aspects
Jacobson, L. (2014) · Comprehensive Physiology · doi:10.1002/cphy.c130036 · Cited by 144
“(339,400), “response” continues to be equated with treatment success.”
New generation antidepressants for depression in children and adolescents: a network meta-analysis
Hetrick, S. E., McKenzie, J. E., Bailey, A. P., Sharma, V., Moller, C. I., Badcock, P. B., Cox, G., Merry, S., & Meader, N. (2021) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd013674.pub2 · Cited by 269
Berlim, M. T., Van den Eynde, F., & Daskalakis, Z. J. (2013) · Depression and Anxiety · doi:10.1002/da.22060 · Cited by 142
Berlim, M. T., McGirr, A., dos Santos, N. R., Tremblay, S., & Martins, R. (2017) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2017.02.015 · Cited by 155
Fava, M., Iosifescu, D. V., Pedrelli, P., & Baer, L. (2009) · Psychotherapy and Psychosomatics · doi:10.1159/000201934 · Cited by 135
Self-citationSelf‐administration of cocaine, cannabis and heroin in the human laboratory: benefits and pitfalls
Haney, M. (2009) · Addiction Biology · doi:10.1111/j.1369-1600.2008.00121.x · Cited by 134
Weobong, B., Weiss, H. A., McDaid, D., Singla, D. R., Hollon, S. D., Nadkarni, A., Park, A.-L., Bhat, B., Katti, B., Anand, A., et al. (2017) · PLOS Medicine · doi:10.1371/journal.pmed.1002385 · Cited by 135
“This is striking because depression tends to return after treatment termination among recently remitted patients, which is one of the reasons physicians are encouraged to keep patients on active medications for at least 4 months following initial remission [23].”
BackgroundMethodThe Depression Treatment Cascade in Primary Care: A Public Health Perspective
Pence, B. W., O’Donnell, J. K., & Gaynes, B. N. (2012) · Current Psychiatry Reports · doi:10.1007/s11920-012-0274-y · Cited by 133
Electroencephalography-Derived Biomarkers of Antidepressant Response
Iosifescu, D. V. (2011) · Harvard Review of Psychiatry · doi:10.3109/10673229.2011.586549 · Cited by 129
Defining Treatment-Resistant Depression: A Comprehensive Review of the Literature
Trevino, K., McClintock, S. M., Fischer, N. M., Vora, A., & Husain, M. M. (2014) · Annals of Clinical Psychiatry · doi:10.1177/104012371402600310 · Cited by 130
Enhanced Visual Motion Perception in Major Depressive Disorder
Golomb, J. D., McDavitt, J. R. B., Ruf, B. M., Chen, J. I., Saricicek, A., Maloney, K. H., Hu, J., Chun, M. M., & Bhagwagar, Z. (2009) · Journal of Neuroscience · doi:10.1523/jneurosci.1003-09.2009 · Cited by 126
“All patients had been medication-free and euthymic for a minimum of 4 months to meet criteria for recovery as per guidelines (Rush et al., 2006).”
BackgroundCraighead, W. E., & Dunlop, B. W. (2014) · Annual Review of Psychology · doi:10.1146/annurev.psych.121208.131653 · Cited by 128
Wiles, N., Thomas, L., Abel, A., Barnes, M., Carroll, F., Ridgway, N., Sherlock, S., Turner, N., Button, K., Odondi, L., et al. (2014) · Health Technology Assessment · doi:10.3310/hta18310 · Cited by 127
Comprehensive Analysis of Remission (COMPARE) with Venlafaxine versus SSRIs
Nemeroff, C. B., Entsuah, R., Benattia, I., Demitrack, M., Sloan, D. M., & Thase, M. E. (2010) · Focus · doi:10.1176/foc.8.4.foc592 · Cited by 126
Self-citationDifficult-to-treat depression: A clinical and research roadmap for when remission is elusive
Rush, A. J., Aaronson, S. T., & Demyttenaere, K. (2019) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/0004867418808585 · Cited by 120
“If we assume that we had no dropouts, about two-thirds eventually reached remission after up to four acute-phase treatment trials (Rush et al., 2006b).”
BackgroundInfluentialSelf-citationCuijpers, P., Karyotaki, E., Ciharova, M., Miguel, C., Noma, H., Stikkelbroek, Y., Weisz, J. R., & Furukawa, T. A. (2023) · European Child & Adolescent Psychiatry · doi:10.1007/s00787-021-01884-6 · Cited by 118
“Third, response as outcome has been criticized, because it is depending on the baseline severity score, which may be unreliable [31].”
BackgroundAthreya, A. P., Neavin, D., Carrillo‐Roa, T., Skime, M., Biernacka, J., Frye, M. A., Rush, A. J., Wang, L., Binder, E. B., Iyer, R. K., et al. (2019) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.1482 · Cited by 114
“46 Finally, we showed in this work that multivariate clustering approaches that use individual depression item scores did not yield clustering patterns at 8 weeks that conformed to accepted definitions of response or remission ( Figure S1 ).”
BackgroundSelf-citationMerkl, A., Schneider, G., Schönecker, T., Aust, S., Kühl, K.-P., Kupsch, A. R., Kühn, A. A., & Bajbouj, M. (2013) · Experimental Neurology · doi:10.1016/j.expneurol.2013.08.017 · Cited by 128
“Remission after chronic stimulation was defined as HAMD-24 scores or MADRS scores of 10 or less after DBS (Rush et al., 2006).”
Möller, H.-J. (2008) · The World Journal of Biological Psychiatry · doi:10.1080/15622970801981606 · Cited by 114
Han, Y., Chen, J., Zou, D., Zheng, P., Li, Q., Wang, H., Li, P., Zhou, X., Zhang, Y., Liu, Y., et al. (2016) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s117146 · Cited by 113
“Outcome measures Response rate was chosen as a primary outcome, being the most consistently reported estimates of acute treatment efficacy.(25,26) Remission rate was also analyzed, as it was arguably more clinically relevant than response rate.”
MethodGrunebaum, M. F., Galfalvy, H. C., Mortenson, L. Y., Burke, A. K., Oquendo, M. A., & Mann, J. J. (2010) · Journal of Affective Disorders · doi:10.1016/j.jad.2009.09.010 · Cited by 113
“This time framewas chosen to approximate ACNP task force recommendations on defining remission (Rush et al., 2006).”
Duru, G., & Fantino, B. (2008) · Current Medical Research and Opinion · doi:10.1185/030079908x291958 · Cited by 112
Holländare, F., Johnsson, S., Randestad, M., Tillfors, M., Carlbring, P., Andersson, G., & Engström, I. (2011) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.2011.01698.x · Cited by 111
“The goal of depression treatment should be full remission (12), and hence, treating the residual symptoms is a key component in the prevention of relapse.”
BackgroundHarkness, K. L., Bagby, R. M., & Kennedy, S. H. (2012) · Journal of Consulting and Clinical Psychology · doi:10.1037/a0027665 · Cited by 111
“This approach addresses biases inherent in deleting patients who drop out of treatment, and ultimately allows for the inclusion of a larger and more representative sample in the analyses.”
BackgroundMethodInfluentialTrivedi, M. H., & Daly, E. (2007) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2007.01.007 · Cited by 115
“2.3 Residual Symptoms and Functional Impairment in Major Depression The goal of depression treatment is now full remission of symptoms (i.e., absence of symptoms), rather than response (Bakish 2001; Rush et al., 2006b).”
BackgroundMethodInfluentialSelf-citationSackeim, H. A., Aaronson, S. T., Bunker, M. T., Conway, C. R., Demitrack, M. A., George, M. S., Prudic, J., Thase, M. E., & Rush, A. J. (2019) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2019.03.021 · Cited by 109
Self-citationMcDonald, W. M., Durkalski, V., Ball, E. R., Holtzheimer, P. E., Pavlicova, M., Lisanby, S. H., Avery, D., Anderson, B. S., Nahas, Z., Zarkowski, P., et al. (2011) · Depression and Anxiety · doi:10.1002/da.20885 · Cited by 108
Self-citationWojnarowski, C., Firth, N., Finegan, M., & Delgadillo, J. (2019) · Behavioural and Cognitive Psychotherapy · doi:10.1017/s1352465819000080 · Cited by 108
Metadata
- Authors
- Rush, A. J., Kraemer, H. C., Sackeim, H. A., Fava, M., Trivedi, M. H., Frank, E., Ninan, P. T., Thase, M. E., Gelenberg, A. J., Kupfer, D. J., Regier, D. A., Rosenbaum, J. F., Ray, O., & Schatzberg, A. F.
- Affiliations
- The University of Texas Southwestern Medical Center (US)
- Stanford Medicine (US)
- University of Pittsburgh (US)
- Emory University (US)
- University of Arizona (US)
- American Psychiatric Association (US)
- Harvard University (US)
- Vanderbilt University (US)
- Corresponding author
- Rush, A John
- ORCID
- Venue
- Neuropsychopharmacology
- Published
- 2006-06-21
- Volume
- 31
- Issue
- 9
- Pages
- 1841-1853
- ISSN
- 0893-133X (ISSN-L)
- 1740-634X
- OpenAlex
- W2039979496
- Cited by
- 707
- References
- 132
- Citations by year
- 2026: 22 · 2025: 23 · 2024: 29 · 2023: 58 · 2022: 30 · 2021: 47 · 2020: 30 · 2019: 47 · 2018: 35 · 2017: 30 · 2016: 41 · 2015: 33 · 2014: 32 · 2013: 36 · 2012: 35
- FWCI
- 4.34
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Neuropsychopharmacology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Social Sciences › Psychology › Experimental and Cognitive Psychology › Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
- Social Sciences › Psychology › Experimental and Cognitive Psychology › Mental Health Research Topics
- Keywords
- major depressive disorder, remission, response, recovery, relapse, recurrence, end points, symptom rating scales, DSM-IV-TR diagnostic criteria, clinical trial results, quality of life
- MeSH terms
- Clinical Trials as Topic, Major Depressive Disorder, Humans, Recurrence, Research Design
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.